Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.

Francesco D'Alo', Stefan Hohaus, Manuela Giachelia, Maria Teresa Voso, Giuseppe Leone

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

7 Citazioni (Scopus)

Abstract

Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells
Lingua originaleEnglish
pagine (da-a)465-471
Numero di pagine7
RivistaLEUKEMIA & LYMPHOMA
Volume2011
Stato di pubblicazionePubblicato - 2011

Keywords

  • Hematopoietic stem cells
  • Myelodysplastic syndrome
  • decitabine
  • gene expression

Fingerprint

Entra nei temi di ricerca di 'Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.'. Insieme formano una fingerprint unica.

Cita questo